Literature DB >> 8931592

Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.

J Guridi1, M T Herrero, M R Luquin, J Guillén, M Ruberg, J Laguna, M Vila, F Javoy-Agid, Y Agid, E Hirsch, J A Obeso.   

Abstract

Nineteen Macaca fascicularis monkeys were divided into four different groups: Group A (n = 3), control; Group B (n = 3), monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); Group C (n = 8), animals treated with MPTP in which the subthalamic nucleus (STN) was unilaterally lesioned by kainic acid injection; in Group D (n = 5), the STN was lesioned prior to MPTP administration. Subthalamotomy resulted in a bilateral improvement of tremor, spontaneous activity, bradykinesia (evaluated by a manual motor test) and freezing in Group C. All these monkeys developed hemichorea contralateral to the lesion. The improvement was maintained and the hemichorea continued until death. The monkeys in group D showed severe hemiballism which persisted throughout MPTP administration and developed parkinsonian signs mainly on the side ipsilateral to the lesion. Analysis of the in situ hybridization of the mRNA coding for glutamic acid decarboxylase (GAD) of MPTP monkeys showed a significant increase in the mean density of silver grains over every labelled neuron in the globus pallidum lateralis (56.8% over control) as well as the globus pallidus medialis (GPM) (45.7% over control) and the substantia nigra reticulata (SNR) (35.8% over control). No significant change was observed in the thalamic nucleus reticularis. Subthalamotomy (Groups C and D) produced a significant reduction in mRNA GAD expression on the side of the lesion in the GPM and the SNR (34% and 42.3%, respectively) with respect to the ipsilateral (non-lesioned) side and also when compared with parkinsonian monkeys. These results confirm and expand, at the cellular level, the paramount role of STN hyperactivity in the pathophysiology of parkinsonism. The therapeutic consequences of these findings for surgical treatment of Parkinson's disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931592     DOI: 10.1093/brain/119.5.1717

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  28 in total

1.  Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

Authors:  H Awad; G W Hubert; Y Smith; A I Levey; P J Conn
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.

Authors:  Nathalie Breysse; Marianne Amalric; Pascal Salin
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

3.  Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.

Authors:  Jose L Lanciego; Maria C Rodríguez-Oroz; Francisco J Blesa; Lydia Alvarez-Erviti; Jorge Guridi; Pedro Barroso-Chinea; Yoland Smith; Jose A Obeso
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

4.  Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode.

Authors:  C Beurrier; P Congar; B Bioulac; C Hammond
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 5.  Milestones in research on the pathophysiology of Parkinson's disease.

Authors:  Thomas Wichmann; Mahlon R DeLong; Jorge Guridi; Jose A Obeso
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

6.  Surgery for Parkinson's disease.

Authors:  J A Obeso; J Guridi; J A Obeso; M DeLong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

Review 7.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

8.  Deep brain stimulation for movement and other neurologic disorders.

Authors:  Mahlon DeLong; Thomas Wichmann
Journal:  Ann N Y Acad Sci       Date:  2012-07-23       Impact factor: 5.691

Review 9.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

10.  Mapping the contribution of single muscles to facial movements in the rhesus macaque.

Authors:  B M Waller; L A Parr; K M Gothard; A M Burrows; A J Fuglevand
Journal:  Physiol Behav       Date:  2008-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.